INTRODUCTION

Colorectal cancer is the third most common tumor and the third leading cause of cancer-related death in man and women in the world. In China, there was an increase of over 376 300 cases of CRC and a total of 191 000 deaths during 2015. Environmental and lifestyle changes, including an altered diet, lack of appropriate physical activity, circadian disruption, and increase in alcohol consumption, have enormously aggravated the burden of CRC. In the past several years, the incidence and mortality of CRC increased rapidly and the onset age was much younger. 

原发性大肠癌是人类第三大常见肿瘤和第三大癌死原因。研究报道，近年来我国结肠癌的发病率和死亡率呈快速上升趋势，2015年我国结肠癌新发病例达37.63万例，死亡病例达19.1万例。环境和生活方式的改变，包括饮食习惯的改变、缺乏适当的身体锻炼、昼夜节律的破坏和酒精摄入量的增加，都极大地加重了结肠癌的负担。近十几年来，结肠癌的发病率和死亡率迅速上升，且发病平均年龄呈下降趋势。
It is promising that therapeutic options for patients have increased substantially, including earlier diagnosis and treatments such as radiotherapy, chemotherapy, and surgical resection, however, the long-term survival of CRC patients remains unsatisfactory. Therefore, a deeper understanding of the underlying molecular mechanisms of CRC is urgently needed to accelerate the development of early detection strategies and effective therapeutic targets.

GINS complex subunit 4, also named SLD5, is a member of the tetrameric complex termed GINS, which is composed of PSF1, PSF2, PSF3, and GINS4. It is evolutionarily well-conserved and plays an essential role in the DNA replication initiation in eukaryotes. GINS complex subunit 4 was also reported to be involved in early embryogenesis in mice and to maintain cell cycle progression and genome integrity in plex subunit 4 was also reported to be involved in early embryogenesis. GINS4 expression was elevated both in bladder cancer tissues and cell lines, and the knockdown of GINS4 inhibited bladder cell growth both in vitro and in vivo. All of these findings suggested that GINS4 might play a significant role in tumorigenesis; however, the relevance of GINS4 in CRC has not been elucidated.

A large amount of evidence indicated that several transcription factors could inhibit cancer cell growth or migration. The zinc finger transcription factor KLF4 was reported to play an important role in tumor development and progression, and was considered as a potential tumor suppressor in some tumors; it can transcriptionally activate NDRG2 by binding with NDRG2 promoter and inhibit CRC cell growth through upregulating p21WAF1/Cip1 and downregulating cyclin D1. In addition, increased KLF4 expression and increased Sp1 expression was a novel molecular mechanism of FOXM1c overexpression and that FOXM1c promoted cancer invasion and metastasis in human pancreatic cancer. Krüppel-like factor 4 played a negative role in gastric cancer cell invasion, which was reversed by upregulation of serine/threonine kinase 33 expression at the transcriptional level. Our previous studies found that loss of KLF4 expression contributed to enhance human gastric cancer EMT and metastasis development and progression through regulating PODXL. However, the underlying molecular mechanism of the tumor-suppressive role of KLF4 in CRC is still vague, and needs to be further investigated.

In the present study, GINS4 was highly expressed in CRC and downregulation of GINS4 could inhibit growth of CRC cells. Furthermore, KLF4 transcriptionally suppressed GINS4 expression in CRC, and the novel KLF4/GINS4 signaling pathway critically regulated CRC proliferation and growth to supply a promising prognostic indicator and an effective therapeutic target for CRC.

2 | MATERIALS AND METHODS

2.1 | Patients and specimens

Sixty-three paired fresh CRC and adjacent normal tissues were collected after radical surgical resection in Shanghai General Hospital from 2015 to 2017 and were stored at -80°C for RNA extraction.

Additionally, 106 paired CRC and adjacent normal tissues were collected from patients diagnosed with CRC at the General Surgery Department of Shanghai General Hospital from 2013 to 2014. All specimens, to construct the TMA, were paraffin-embedded, validated by H&E staining, and finally examined by two independent pathologists. The final IHC results in TMA covered 106 CRC tissues and 108 adjacent normal tissues. None of the patients had received radiotherapy or chemotherapy before surgery. Clinicopathological characteristics were diagnosed and confirmed by two independent pathologists according to the guidelines of the American Joint Committee on Cancer, and are presented in Table 1. Written informed consent was obtained from each statement before enrolling in the study. The study was approved by the Ethical Committee for Clinical Research of Shanghai General Hospital.

2.2 | Cell lines and culture conditions

Human CRC cell lines (SW620, SW480, HCT29, RKO, CACO2, HCT116, LoVo, and HCT8) were purchased from the Type Culture Collection of the Chinese Academy of Science (Shanghai, China). All cells were cultured in DMEM (Gibco) supplemented with 10% FBS (Gibco) and maintained at 37°C in a humidified incubator with 5% CO₂.

2.3 | RNA extraction and qRT-PCR

Total RNA from CRC tissues and cells was extracted using RNAsio Plus Reagent (Takara) according to the manufacturer’s protocol. RNA (500 ng) was reverse transcribed with the PrimeScript RT reagent kit (Takara). cDNA was amplified with SYBR Premix Ex Taq (Takara). The following primers were used for qRT-PCR: GINS4, forward 5'-GTAAGCCCTGTAATCCCAGCA-3' and reverse 5'-GTTCAAGCGATTCTCCTG GC-3'; KLF4, forward 5'-AAAAAAGAATTCATGAGGCAGCCACTG-3' and reverse 5'-GTTCAAGCGATTCTCCTG GC-3'; KLF4, forward 5'-AAAAAAGAATTCATGAGGCAGCCACTG-3' and reverse 5'-GTTCAAGCGATTCTCCTG GC-3'; and GAPDH, forward 5'-GGGGAAGGTGAAGGTCGGAGT-3' and reverse 5'-GGGGAAGGTGAAGGTCGGAGT-3'. The gene expression levels were determined by the 2−ΔΔCt method with GAPDH as the internal control mRNA. Each qRT-PCR was carried out in triplicate.

2.4 | Protein extraction and western blot analysis

Total protein was lysed using RIPA buffer with the protease inhibitor PMSF (Beyotime Biotechnology), and the concentration of protein was measured with a BCA Protein Assay Kit (Tiangen). Protein lysates were separated by SDS-PAGE and then transferred onto PVDF membranes (Millipore). The membranes were blocked in 5% skim milk at room temperature for 1.5 hours followed by incubating with specific primary Abs at 4°C overnight: GINS4 (1:1000; Sigma), KLF4 (1:100; Santa Cruz Biotechnology), BCL2 (1:1000; Cell Signaling Technology), Ki67 (1:5000; Abcam), Cyclin D1 (1:10 000; Abcam),
Erk1/2 (1:1000; Cell Signaling Technology), phospho-Erk (1:1000; Cell Signaling Technology), GAPDH (1:1000; Cell Signaling Technology), AKT (1:1000; Abcam), and phospho-AKT (1:1000; Abcam, USA). The membranes were then incubated with a HRP-conjugated anti-mouse or anti-rabbit secondary Ab (Cell Signaling Technology) at room temperature for 1.5 hours. After the membranes washed 3 times with TBST, protein bands were detected using ECL chemiluminescent reagent (Millipore).

### 2.5 | Transient transfection and lentiviral transduction

For transient transfection, the pcDNA3.1-KLF4 plasmid and negative control vector were synthesized from Obio Technology. HCT8 and RKO cells cultured to 60%-70% confluence were transfected with the above oligonucleotides and vectors using Lipofectamine 2000 in accordance with the manufacturer’s instructions (Invitrogen). For lentivirus transfections, the shRNA plasmid for silencing GINS4 and the control-shRNA plasmid and were purchased from Genechem. The target sequences of the shRNA were as follows: sh-GINS4-1: 5′-CCTATTTCCCATGATTCCTTCATA-3′; sh-GINS4-2: 5′-GAGCAGAGGGACTACGTGATT-3′. HCT8 and RKO cells in logarithmic growth phase, cultured in 6-well plates, were transected with lentiviral transduction were purified with puromycin (Invitrogen). Cells transduced with control-shRNA plasmid (HCT8-scramble or RKO-scramble) served as controls. Gene silencing and overexpression were monitored by qRT-PCR and western blot analysis.

### 2.6 | Cell growth assay

Cell plate colony formation assays were carried out to evaluate cellular growth in vitro. Cells were seeded into 6-well plates with 1000 cells/well and cultured at 37°C in a humidified atmosphere with 5% CO₂. They were fixed in methyl alcohol for 15 minutes, then dyed with 0.1% crystal violet solution.
for 15 minutes after 14 days of culture. For the CCK-8 assay, 5000 cells/well were plated in 96-well cell culture plates. After 24 hours, 10 μL/well of CCK-8 (Dojindo) was added. The absorbance was measured at 450 nm on a Gen5 microplate reader (Bio-Tek). The CCK-8 assay was carried out at the indicated time point of every day for 4 days. For the EdU (RiboBio) cell growth assay, cells were plated into 24-well plates and cultured for 24 hours. The cells were incubated with 50 μmol/L EdU for 2 hours before fixation, permeabilization, and EdU staining. Cell nuclei were stained with Hoechst 33342 for 30 minutes. Images were captured using a fluorescence microscope (Leica). The percentage of EdU-positive cells was calculated as follows: (EdU-positive cells/Hoechst-positive cells) × 100%. All experiments were carried out in triplicate.

2.7 | Flow cytometric analysis

For the cell cycle assay, CRC cells were harvested and fixed in 70% ethanol overnight at 4°C. After being washed with PBS, the cells were stained with 0.5 mL propidium iodide/RNase staining buffer at room temperature for 30 minutes. The cell apoptosis assay was undertaken using the Annexin V-PE/7-AAD Apoptosis Detection Kit (MultiSciences Biotech) according to the manufacturer’s protocol. Briefly, cells were suspended in 100 μL binding buffer, then 5 μL fluorochrome-conjugated annexin V-PE was added. After incubation for 15 minutes at room temperature, the cells were resuspended in 200 μL binding buffer and 10 μL 7-AAD was added. The apoptotic cells were analyzed by a flow cytometer (BD Biosciences).

2.8 | Immunohistochemistry

The TMA was first deparaffinized in xylene, rehydrated in the gradient ethanol and prepared for antigen retrieval, then boiled in sodium citrate solution (0.01 M, pH 6.0) for 5 minutes to block endogenous peroxidase activity. The TMA was exposed to 3% hydrogen peroxide for 15 minutes after 14 days of culture. For the CCK-8 assay, 5000 cells/well were plated in 96-well cell culture plates. After 24 hours, 10 μL/well of CCK-8 (Dojindo) was added. The absorbance was measured at 450 nm on a Gen5 microplate reader (Bio-Tek). The CCK-8 assay was carried out at the indicated time point of every day for 4 days. For the EdU (RiboBio) cell growth assay, cells were plated into 24-well plates and cultured for 24 hours. The cells were incubated with 50 μmol/L EdU for 2 hours before fixation, permeabilization, and EdU staining. Cell nuclei were stained with Hoechst 33342 for 30 minutes. Images were captured using a fluorescence microscope (Leica). The percentage of EdU-positive cells was calculated as follows: (EdU-positive cells/Hoechst-positive cells) × 100%. All experiments were carried out in triplicate.

2.9 | Animal experiments

To investigate primary tumor growth, approximately $5 \times 10^6$ cells from stable cell lines (HCT8-shGINS4-1 and HCT8-scramble, and RKO-shGINS4-1 and RKO-scramble) were s.c. injected into 4-week-old male BALB/c athymic nude mice. Tumor volume was calculated every 7 days using the following formula: volume = width$^2$ × length × 0.5. All the mice were killed 5 weeks later, and xenografts were removed and weighed. All mice were used in line with the guidelines of Institutional Animal Care of Shanghai General Hospital.

2.10 | Promoter reporter and dual-luciferase assay

Colorectal cancer cells were transfected with the full-length reporter plasmid (pGL4.27-GINS4-wild) or the mutated promoter (pGL4.27-GINS4-mut) with pCDNA3.1-KLF4 and pRL. The GINS4 promoter activity in these cells was normalized through cotransfection of a Renilla luciferase reporter containing a full-length Renilla luciferase gene. The resulting luciferase activity in the cells was quantified using a dual luciferase assay system (Promega) 36 hours after transfection. The effects of KLF4 on luciferase reporter plasmids were calculated with the ratio of firefly luciferase/Renilla luciferase activity. All experiments were independently repeated in triplicate.

2.11 | Chromatin immunoprecipitation assay

The ChIP assay kit (Millipore) was prepared for ChIP assays in HCT8 and RKO cells ($4 \times 10^6$) according to the manufacturer’s protocol, transfected with KLF4 or vector, after cross-linking, quenched with glycine, and protein and DNA were lysed by sonication. The supernatants were incubated overnight at 4°C with 2 μg anti-KLF4 (#AF3640; R&D Systems) and IgG served as a normal control. After purification, the resulting precipitated DNA fragments were analyzed using PCR to amplify fractions of the GINS4 promoter with the primers 5′-TCGTCCGATCCCAGGCTTCAAG-3′ (forward) and 5′-CCAGCGATCCTCCCCACCTCAG-3′ (reverse). The DNA of PCR products were resolved electrophoretically on a 2% agarose gel and photographed using ultraviolet rays.

2.12 | Statistical analysis

Data analyses were undertaken using SPSS 23.0 software. Paired and unpaired continuous variables were compared by Student’s t test or the Mann-Whitney U test. The correlations between GINS4 expression and clinicopathological features were determined by Fisher’s exact test and the $\chi^2$ test. The correlation between GINS4 and KLF4 expression was examined by Spearman’s correlation test. Survival curves were drawn using the Kaplan-Meier method and Cox multivariate analysis, and were analyzed by log-rank tests. In all of the tests, $P < .05$ was considered statistically significant.
3 | RESULTS

3.1 | Overexpression of GINS4 indicated poor clinical outcome of CRC

Using bioinformatics analysis, GINS4 was markedly increased both in CRC tissues and colon adenoma from the Oncomine database (https://www.oncomine.org) (Figure 1A). Thereafter, we sought to verify the expression of GINS4 in 63 paired CRC samples. Compared with the levels in adjacent normal mucosa tissues, the results of qRT-PCR indicated that the mRNA expression level of GINS4 was significantly upregulated in 49 (77.78%) fresh CRC clinical samples detected by quantitative real-time PCR.

C. Level of GINS4 in CRC tissues was determined by western blotting. E-G, GINS4 expression between T1 and T2 vs T3 and T4 (E, $P = .022$), grade I vs grade II and III (F, $P = .024$), TNM stage I and II vs TNM stage III and IV (G, $P < .0001$). H, Kaplan-Meier survival analysis (log-rank test) showed that CRC patients with strong positive expression of GINS4 had a lower overall survival and disease-free survival than those with negative and weak positive expression. **$P < .01$, ***$P < .001$
clinopathologic characteristics of the TMAs are listed in Table 1. We observed that GINS4 was positively stained in 88 (52 strong positive and 36 weak positive) cases among 106 specimens (Figure 1C). Western blot analysis further confirmed that GINS4 protein was elevated in CRC tissues (Figure 1D). Expression of GINS4 was positively associated with tumor stage \( (P = .022) \), differentiation \( (P = .024) \), and TNM stage \( (P = .001) \) (Figure 1E-G, Table 1). However, there was no significant correlation between the level of GINS4 expression and age, gender, node stage, nerve invasion, vessel invasion, tumor size, or location (Table 1). The IHC results in TMA indicated that the level of GINS4 expression serves as a vital role in CRC development and progression. Our findings strongly illustrated that GINS4 plays a significant role in CRC development and progression.

We then determined whether GINS4 acted as a valuable biomarker for the survival and prognosis of CRC patients. First, the univariate analysis indicated that patients with higher levels of GINS4 had poorer OS \( (P = .017) \) and DFS \( (P = .011) \) compared with those with lower levels of GINS4 (Figure 1H). The TNM stages and tumor location were significantly related to OS and DFS, based on the univariate analysis (Table 2). Second, according to the multivariate survival analysis based on the above factors in the Cox proportional hazards model, GINS4 expression was significantly related with OS \( (HR = 0.470; 95\% CI, 0.248-0.892; P = .021) \) and DFS \( (HR = 0.486; 95\% CI, 0.274-0.861; P = .013) \); TNM stage and tumor location were both closely related to OS and DFS (Table 2). These findings indicated that GINS4 played a vital role in CRC development and progression and could function as a valuable target for CRC therapy and diagnosis. Taken together, our findings suggested that GINS4 could serve as a valuable and unique indicator of CRC patient prognosis.

### 3.2 | Knockdown of GINS4 expression inhibits growth in vitro and in vivo

To investigate the function of altered GINS4 expression on the growth of CRC cells, GINS4 was not only upregulated in RKO and HCT8 cell lines compared with other CRC cell lines, through qRT-PCR and western blot analysis (Figure 2A,B). Hence, we chose HCT8 and RKO cells to establish stable cell lines to explore the influence of GINS4 expression in the biological processes of CRC cells. HCT8 and RKO cells transfected with lentiviral shGINS4-1 or shGINS4-2 vector were applied in this study, and western blotting and real-time PCR were used to evaluate the efficiency of shGINS4-1 and -2. The results showed that shGINS4-1 and -2 effectively blocked GINS4 protein (Figure 2C,D). The CCK-8 and EdU growth assay results indicated that low levels of GINS4 expression inhibited RKO and HCT8 growth (Figure 3A,B). Furthermore, the colony formation assay showed that GINS4 knockdown inhibited colony formation both in HCT8 and RKO cells (Figure 3C). In the s.c. tumor model, the 4 stable cell lines HCT8-shGINS4-1/HCT8-scramble and RKO-shGINS4-1/RKO-scramble were s.c. injected into nude mice. After 10 days, the tumor volume was monitored twice every week. The results showed that the volume and weight of the xenograft tumor from HCT8-shGINS4-1/RKO-shGINS4-1 cells were remarkably smaller than those in the HCT8-scramble/RKO-scramble group (Figure 4A-C). Furthermore, IHC analysis showed that GINS4 expression was significantly downregulated in HCT8-shGINS4-1/RKO-shGINS4-1 tumors (Figure 4D). Our findings primarily indicated that GINS4 served as an oncogene and knockdown of GINS4 expression can inhibit the growth of CRC cells in vitro and in vivo.

### 3.3 | Knockdown of GINS4 suppresses cell cycle progression and promotes cell apoptosis by inhibiting PI3K/AKT and MAPK/ERK pathways

As we know, equilibrium between cell proliferation and cell apoptosis is important for cell growth. To explore how GINS4 regulates CRC cell growth, we investigated whether the lower expression of GINS4 inhibited the transition from G0/G1 phase to S phase (Figure 5A). Downregulated expression of GINS4 remarkably reduced the expression of G0/G1 phase transition regulator Cyclin D1 and Ki-67 in HCT8 and RKO cells (Figure 5D). In the s.c. tumor model, IHC and western blot analyses showed that cell proliferation marker Ki-67 was significantly downregulated in HCT8-shGINS4-1/RKO-shGINS4-1 tumors (Figures 4B and 5C). As expected, determined by annexin V-PE/7-AAD apoptosis assay, GINS4 also inhibited CRC cells apoptosis. Furthermore, the antiapoptotic protein Bcl-2 was decreased in HCT8 and RKO cells when expression of GINS4 was downregulated (Figure 5E). Our previous study indicated that GINS4 inhibited cell apoptosis in vitro and promoted cell growth and metastasis in vitro and in vivo in gastric cancer; GINS4 directly combined and activated Rac1/CDC42, thereby activating their downstream pathways, including the PI3K/AKT, MAPK/ERK, and PTEN pathways in gastric cancer.23 We examined the activity of the 3 signaling pathway cascades, and found that GINS4 knockdown only decreased the expression of pERK and pAKT in CRC cell lines (Figure 5D). Therefore, the activity of MAPK/ERK and PI3K/AKT pathways was suppressed when GINS4 was downregulated (Figure 5D). These results indicated that GINS4 knockdown affected cell proliferation and apoptosis through inhibiting the MAPK/ERK and PI3K/AKT pathways in CRC cells.

### 3.4 | Krüppel-like factor 4 downregulates GINS4 expression by directly binding to its promoter

To explore the mechanisms underlying upregulated GINS4 in CRC tissues and cell lines, the sequences of GINS4 gene promoter for potential transcription factor binding sites were analyzed by using the JASPAR (http://jaspar.genereg.net/) database and Alggen-PROMO (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3). The results showed that there were 2 putative KLF4-binding sites in the GINS4 promoter region containing potential KLF4-binding elements, 5′-CACCC-3′ and 5′-(G/A)(G/A)GG(C/T) G(C/T)-3′ (Figure 6A).24,25 Furthermore, statistical analysis of The
Cancer Genome Atlas datasets revealed that the expression of GINS4 was negatively correlated with the expression of KLF4 in the 663 CRC specimens (Figure 6B); a negative correlation between GINS4 and KLF4 in CRC cell lines was already determined (Figure 2A,B). We elevated the expression of KLF4 in CRC cells, and the results indicated that the overexpression of KLF4 in HCT8 and RKO cells led to decreased expression of GINS4 mRNA and protein (Figure 6C). To further confirm whether KLF4 could transcriptionally inhibit GINS4, the full-length promoter of GINS4 was cloned to pGL4.27 vector, and we also mutated the 2 binding sites (Figure 6A). Furthermore, we cotransfected pGL4.27-GINS4-wild or pGL4.27-GINS4-mutant with pCDNA3.1-KLF4 or control into HCT8 and RKO cells. We found that KLF4 prominently suppressed the wild GINS4 promoter activity but not mutant GINS4 promoter activity in HCT8 and RKO cells.

### TABLE 2  
Univariate and multivariate analysis for overall survival (OS) and disease-free survival (DFS) in patients with colorectal cancer

| Parameters                  | OS          | DFS          |
|-----------------------------|-------------|--------------|
|                             | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis |
|                             | $\chi^2$ | $P$ | HR(95%CI) | $P$ | $\chi^2$ | $P$ | HR(95%CI) | $P$ |
| Age                         |            |              |            |              |            |              |            |              |
| <65                         | 51         | 3.633        | .057       | 3.707        | .054       |
| ≥65                         | 55         |              |            |              |            |              |            |              |
| Gender                      |            |              |            |              |            |              |            |              |
| Male                        | 55         | 0.068        | .794       | 0.283        | .595       |
| Female                      | 51         |              |            |              |            |              |            |              |
| T stage                     |            |              |            |              |            |              |            |              |
| T1+T2                       | 12         | 1.132        | .287       | 2.286        | .131       |
| T3+T4                       | 94         |              |            |              |            |              |            |              |
| N stage                     |            |              |            |              |            |              |            |              |
| N0+N1                       | 82         | 3.082        | .079       | 3.585        | .058       |
| N2+N3                       | 24         |              |            |              |            |              |            |              |
| TNM stage                   |            |              |            |              |            |              |            |              |
| I + II                      | 51         | 5.449        | .020*      | 0.520 (0.275-0.983) | .044*    | 5.459        | .019*      | 0.556 (0.316-0.979) | .042* |
| III+IV                      | 55         |              |            |              |            |              |            |              |
| Nerve invasion              |            |              |            |              |            |              |            |              |
| Yes                         | 27         | 2.478        | .115       | 2.986        | .084       |
| No                          | 79         |              |            |              |            |              |            |              |
| Vessel invasion             |            |              |            |              |            |              |            |              |
| Yes                         | 25         | 0.315        | .574       | 0.706        | .401       |
| No                          | 81         |              |            |              |            |              |            |              |
| Differentiation             |            |              |            |              |            |              |            |              |
| Well                        | 19         | 1.615        | .204       | 2.375        | .123       |
| Moderate+Poor               | 87         |              |            |              |            |              |            |              |
| Tumor size                  |            |              |            |              |            |              |            |              |
| <5cm                        | 59         | 0.076        | .783       | 0.029        | .866       |
| ≥5cm                        | 47         |              |            |              |            |              |            |              |
| Tumor location              |            |              |            |              |            |              |            |              |
| Right                       | 41         | 4.927        | .026*      | 2.125 (1.152-3.921) | .016*    | 5.366        | .021*      | 2.072 (1.922-3.600) | .010* |
| Left and Rectal cancer      | 65         |              |            |              |            |              |            |              |
| GINS4 expression            |            |              |            |              |            |              |            |              |
| Negative and weak positive  | 54         | 5.733        | .017*      | 0.470 (0.248-0.892) | .021*    | 6.446        | .011*      | 0.486 (0.274-0.861) | .013* |
| Strong positive             | 52         |              |            |              |            |              |            |              |

Abbreviations: HR: hazard ratio; CI: confidence interval.  
*P < .05.
To explore whether KLF4 directly regulates GINS4 expression, we used the ChIP assay and observed that KLF4 indeed bound to the GINS4 promoter in HCT8 and RKO cells (Figure 6E). In summary, these results showed that KLF4 downregulated GINS4 expression by directly binding to GINS4 promoter.

3.5 Combination of KLF4 and GINS4 levels shows prognostic ability in CRC patients

To further verify the correlation between the expression of KLF4 and GINS4 in the CRC cases, we undertook qRT-PCR to analyze KLF4 expression in the same CRC specimens used in GINS4. The results showed that the level of KLF4 was lower in CRC tissues compared to normal colorectal mucosa tissues (Figure 7A). Further analysis showed that the correlation between GINS4 and KLF4 in CRC tissues compared to normal colorectal mucosa tissues was negative, with statistical significance (Figure 7B). Moreover, pairwise comparisons indicated that patients with high KLF4 (positive) and low GINS4 (negative) staining levels had significantly better OS and DFS than patients with low KLF4 (negative) and high GINS4 (positive) staining (Figure 7E). This indicated that the combination of KLF4 and GINS4 levels could be a useful predictor of clinical prognosis in CRC patients.

4 DISCUSSION

In this report, it was found that GINS4 served as a significant prognostic biomarker and promoted CRC growth by inhibiting cell apoptosis and accelerating cell cycle and colony formation progression, which are the vital characteristics of cancer progression. As a tumor suppressor in CRC was reported in many previous research, KLF4 downregulated GINS4 at the transcriptional level by directly binding to the GINS4 promoter domain region, establishing a novel KLF4/GINS4 signaling pathway that regulated growth of CRC. Taken together, we showed that lost expression of KLF4, a transcriptional repressor of GINS4, resulted in overexpression of GINS4 and ultimately promoted growth and proliferation of CRC.
FIGURE 3  GINS4 complex subunit 4 (GINS) knockdown inhibits colorectal cancer cell growth in vitro. A, CCK-8 growth assay was used to examine the knockdown of GINS4 expression on HCT8 and RKO cells. B, EdU assay was used to analyze the proliferative activity of HCT8 and RKO cells. C, Colony formation assay was used to determine whether knockdown of GINS4 expression inhibited the ability of colony formation in HCT8 and RKO cells. Three independent experiments were carried out for each group. *P < .05, **P < .01, ***P < .001. OD, optical density
FIGURE 4  GINS4 complex subunit 4 (GINS) knockdown inhibits colorectal cancer growth in vivo. A, Tumors were removed 38 days after HCT8-shGINS4-1/HCT8-scramble and RKO-shGINS4-1/RKO-scramble cells were s.c. injected. B, GINS4 mRNA and protein level and Ki-67 protein level in tumors with HCT8-shGINS4-1/RKO-shGINS4-1 was significantly lower than that in tumors with HCT8-scramble/RKO-scramble. C, Tumor weight of RKO and HCT8 cells. Tumor volumes of RKO and HCT8 cells measured every 7 days (5 times in total) were analyzed. D, Representative images of GINS4 immunohistochemical staining in tissues of xenografts (magnification, 200× and 400×). *P < .05, **P < .01
FIGURE 5  GINS complex subunit 4 (GINS4) knockdown suppresses colorectal cancer cell cycle progression and promotes cell apoptosis by inhibiting PI3K/AKT and MAPK/ERK pathways.  
A. Flow cytometry analysis of cell cycle of HCT8 and RKO cells and related data statistics.  
B. Flow cytometry analysis of cell apoptosis and cell cycle of HCT8 and RKO cells and related data statistics.  
C. Representative images of Ki-67 immunohistochemical staining in tissues of xenografts from HCT8 and RKO cells (magnification, 200× and 400×).  
D. Different expression of pathways, cell cycle-related, apoptosis-related and growth marker proteins (pERK1/2, pAKT, cyclin D1, Bcl-2, and Ki-67) in HCT8 and RKO cells. All experiments were independently repeated in triplicate in each group. All data are represented as mean ± SD. *P < .05, **P < .01, #P > .05.
Krüppel-like factor 4 (KLF4) downregulates GINS complex subunit 4 (GINS4) expression by directly binding to its promoter. A, Two putative KLF4-binding sites in the GINS4 promoter region and the 2 mutated binding sites. B, The Cancer Genome Atlas datasets show GINS4 was negatively correlated with KLF4 from 493 colon cancer and 171 rectal cancer patients ($r = -0.23$, $P < .0001$). C, mRNA and protein levels of GINS4 were reduced when KLF4 expression was overexpressed in HCT8 and RKO cells. D, Luciferase reporter assay indicated that KLF4 could suppress the promoter activities of GINS4 both in HCT8 and RKO cells. E, In HCT8 and RKO cells, ChIP assay indicated KLF4 binding sites were across the GINS4 promoter region. Immunoprecipitated DNA products were subjected to PCR analysis to amplify a 230-bp region and presented in 2% agarose gel. *$P < .05$, **$P < .01$. 
Combination of Krüppel-like factor 4 (KLF4) and GINS complex subunit 4 (GINS4) levels is useful for predicting clinical prognosis in colorectal cancer (CRC) patients. A, Relative mRNA expression of KLF4 in 63 CRC tissues compared to paired adjacent normal tissues. B, Correlation between KLF4 and GINS4 mRNA in 63 CRC tissues was also negative ($r = -0.329, P = .0084$). C, D, Relationship between KLF4 and GINS4 in CRC tissues (200×) (C; $r = -0.210, P = .0308$) and normal mucosa (D; $r = -0.230, P = .0177$), detected by immunohistochemistry, were both weakly negatively related. E, Prognostic values of GINS4 combined with KLF4. *$P < .05$, **$P < .01$, ***$P < .001$. 

![Figure 7](image-url)
GINS complex subunit 4 is a member of the GINS family of proteins that plays a vital role in initiation of DNA replication and elongation, and also accelerates the G1/S phase transition in the cell cycle. \(^{27,28}\) Elevated expression of PSF1 (a member of the GINS family) has been confirmed in different cancers, eg, in cancer-initiating cells or cancer stem cells related to a mice tumor cell transplantation model with high PSF1 promoter activity. \(^{16,27}\) In this study, we proved that GINS4 was an oncogene from different aspects. First, GINS4 expression was markedly increased both in CRC tissues and cell lines. Second, further analysis of the correlation between TMA clinicalpathologic characteristics of the CRC patients from whom the TMA specimens were achieved indicated that GINS4 expression was positively related with CRC advanced tumor stage, poor differentiation, and TNM stage. Univariate and multivariate survival analyses indicated that CRC patients with higher GINS4 expression experienced low OS and DFS. Third, we generated stable CRC cell lines to undertake in vitro and in vivo assays. Using CCK-8, EdU, and colony formation assays, we found that the GINS4 knockdown inhibited the growth of CRC cells, which was also verified by in vivo tumor xenograft assays, and that GINS4 knockdown inhibited growth and the cell cycle and accelerated cell apoptosis progression in vitro, using flow cytometric analyses. Finally, our results were consistent with a previous study in which elevated expression of GINS4 was detected in human bladder cancer cells, and GINS4 knockdown substantially suppressed bladder cancer cell growth. \(^{16}\) In summary, our findings underscored that GINS4 serves as a tumor oncogene that could promote CRC growth.

The canonical ERK1/2 signal pathway, known as a member of the MAPK family, is often deregulated in many cancers. \(^{30,31}\) Activation of ERK1/2 was reported to stimulate cell growth and inhibit cell apoptosis through many mechanisms, including the maintenance of activated Cyclin D1 and enhanced AP-1 activity. \(^{32,33}\) The PI3K/AKT signaling pathway is also one of the most frequently activated pathways and modulates cell growth and apoptosis in various tumors. \(^{34,35}\) A novel study reported that the PI3K/AKT signaling pathway increased C-myc and facilitated cell growth in CRC. \(^{36}\) Here, our results showed that GINS4 knockdown simultaneously triggered apoptosis and cell cycle arrest and suppressed the MAPK/ERK and PI3K/AKT signaling pathways, which are 2 main downstream pathways of GINS4 identified in our previous study. \(^{23}\)

Although the molecular basis of GINS4 overexpression in cancer cells is still vague, a recent study showed that GINS4 protein could be stabilized by lymphoid-specific helicase in nonsmall-cell lung cancer. \(^{13}\) Transcription factors played a significant role in the development of tumors. Our recent study suggested that SIX1 could promote cancer cell migration and invasion through increasing vimentin expression at the transcriptional level directly by binding to the promoter domain of vimentin in gastric cancer. \(^{37}\) Our previous studies found that KLF4 was downregulated both in gastric cancer and pancreatic cancer and regulated the expression of a vast number of oncogenes that are involved in many cellular functions, ranging from differentiation to growth, metastasis, and EMT. Loss of KLF4 expression contributed to human gastric cancer EMT and metastasis by regulating PODXL. \(^{21}\) Krüppel-like factor 4 suppressed pancreatic cancer EMT and metastasis by reducing the expression of caveolin-1 through directly binding the promoter region of caveolin-1. \(^{38}\) Furthermore, KLF4 expression was at a significantly low level and loss of KLF4 was an independent predictor of survival and recurrence in colon cancer. \(^{39}\) and an interferon-inducible gene, IFITM3, could be negatively regulated by KLF4 at the transcription level in colon cancer. \(^{40}\) In the present study, qRT-PCR, western blot, the IHC results in TMA combined with our clinical data indicated that KLF4 was downregulated in CRC tissues compared with paired adjacent normal tissues. We found that overexpression of KLF4 caused low levels of GINS4 in CRC. Furthermore, bioinformatics analysis from JASPAR and AlgenePROMO predicted that there were 2 binding sites in the GINS4 promoter related to the putative KLF4 binding motif; we synthesized the wild full-length promoter of GINS4 and mutated the 2 binding sites. Luciferase reporter assay confirmed that KLF4 can bind to particular GINS4 promoter elements and transcriptionally inhibit GINS4 expression. Downregulation of miR-370 could suppress GINS4 expression in bladder cancers, \(^{16}\) and our recent study showed that circMLLT10 served as a miR-509-3p sponge and promoted gastric cancer cell growth and metastasis by increasing GINS4 expression and activating Rac1 and CDC42. \(^{23}\) Therefore, the relationships between noncoding RNA and KLF4 in regulating GINS4 require further study, which might contribute to exploring the progression of CRC.

In summary, based on our clinical and experimental evidence, we highlighted that GINS4 was a vital oncogene in CRC and found that its expression was remarkably elevated in both CRC cell lines and clinical specimens. Elevated GINS4 expression promoted CRC growth in vitro and in vivo and it was transcriptionally inhibited by KLF4, which served as a crucial tumor-suppressive transcriptional factor in CRC. Fundamentally, we not only determined that GINS4 might act as a valuable prognostic biomarker of CRC, but also revealed the aberrant KLF4/GINS4 signaling pathway in CRC, which could provide significant new insights into the development of novel therapies for CRC.

ACKNOWLEDGMENTS

This work was ratified by the Ethics Committee of Shanghai General Hospital. All animals were used according to the Shanghai General Hospital Animal Care and Use Guidelines. Written informed consents was obtained from all patients. This work was supported by grants from the National Natural Science Foundation of China (81772527), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20161425), Shanghai Jiaotong University Medical Cross Fund (YG2017MS28), Shanghai Songjiang Science and Technology Project Fund (185JKJGG23 and 195JKJGG22).

DISCLOSURE

The authors declare no conflicts of interest in this article.

ORCID

Zeyin Rong https://orcid.org/0000-0003-0005-2209
Chen Huang https://orcid.org/0000-0002-1840-5765
REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30.
2. Qu X, Yan X, Qin H, et al. c-Myb promotes growth and metastasis of colorectal cancer through c-fos-induced epithelial-mesenchymal transition. Cancer Sci. 2019;110(10):3183-3196.
3. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-132.
4. Ladabaum U, Marnathla A, Meester RGS, et al. Cost-effectiveness and national effects of initiating colorectal cancer screening for average-risk persons at age 45 years instead of 50 years. Gastroenterology. 2019;157(1):137-148.
5. Weinberg BA, Marshall JL, Salem ME. The growing challenge of young adults with colorectal cancer. Oncology. 2017;31(5):381-389.
6. Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16(12):713-732.
7. Guan Q, Zeng Q, Yan H, et al. A qualitative transcriptional signature for the early diagnosis of colorectal cancer. Cancer Sci. 2019;110(10):3225-3234.
8. Chen D, Li Y, Zhang X, et al. Ubiquitin ligase TRIM65 promotes colorectal cancer metastasis by targeting ARHGAP35 for protein degradation. Oncogene. 2019;38(37):6429-6444.
9. Fujikawa S, Sun Y, Luo J, et al. miR-150 functions as a tumour suppressor in human colorectal cancer by targeting c-Myb. J Cell Mol Med. 2014;18(10):2125-2134.
10. Huang C, Shen JC, Qiu ZJ, et al. Clinical comparison of laparoscopy vs open surgery in a radical operation for rectal cancer: A retrospective case-control study. World J Gastroenterol. 2015;21(48):13532-13541.
11. Kamada K, Kubota Y, Arata T, et al. Structure of the human GINS complex and its assembly and functional interface in replication initiation. Nat Struct Mol Biol. 2007;14(5):388-396.
12. Labib K, Gambus A. A key role for the GINS complex at DNA replication forks. Trends Cell Biol. 2007;17(6):271-279.
13. Gouge CA, Christensen TW. Drosophila Sld5 is essential for normal cell cycle progression and maintenance of genomic integrity. Biochem Biophys Res Commun. 2010;400(1):145-150.
14. Nagahama Y, Ueno M, Haraguchi N, et al. PSF3 marks malignant colon cancer and has a role in cancer cell proliferation. Biochem Biophys Res Commun. 2010;392(2):150-154.
15. Yang R, Liu X, Chen L, et al. LSH interacts with and stabilizes GINS4 complex subunit 4, a prognostic biomarker and reversely mediated by Krüppel-like factor 4. Mol Cancer. 2019;18(1):126.
16. Yamane K, Naito H, Wakabayashi T, et al. Regulation of SLD5 gene expression by miR-370 during acute growth of cancer cells. Sci Rep. 2016;6:30941.
17. Laissie P. The forkhead-box family of transcription factors: key molecular players in colorectal cancer pathogenesis. Mol Cancer. 2019;18(1):5.
18. Ma Y, Wu L, Liu X, et al. KLF4 inhibits colorectal cancer cell proliferation dependent on NDRG2 signaling. Oncol Rep. 2017;38(2):975-984.
19. Shi M, Cui J, Du J, et al. A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Clin Cancer Res. 2014;20(16):4370-4380.
20. Kong F, Sun T, Kong X, et al. Krüppel-like Factor 4 Suppresses Serine/Threonine Kinase 33 Activation and Metastasis of Gastric Cancer through Reversing Epithelial-Mesenchymal Transition. Clin Cancer Res. 2018;24(10):2440-2451.
21. Zhang J, Zhu Z, Huang C, et al. PODXL, negatively regulated by KLF4, promotes the EMT and metastasis and serves as a novel prognostic indicator of gastric cancer. Gastric Cancer. 2019;22(1):48-59.
22. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007;6:24.
23. Zhu Z, Yu Z, Huang C, et al. The novel GINS4 axis promotes gastric cancer growth and progression by activating Rac1 and CDC42. Theranostics. 2019;9(26):8294-8311.
24. Garrett-Sinha LA, Eberspaecher H, Seldin MF, de Crombrugghe B. A gene for a novel zinc-finger protein expressed in differentiated epithelial cells and transiently in certain mesenchymal cells. J Biol Chem. 1996;271(49):31384-31390.
25. Shields M, Yang VW. Identification of the DNA sequence that interacts with the gut-enriched Kruppel-like factor. Nucleic Acids Res. 1998;26(3):796-802.
26. Shie JI, Chen ZY, Tseng CC, et al. Gut-enriched Kruppel-like factor suppresses cyclin D1 promoter activity through Sp1 motif. Nucleic Acids Res. 2000;28(15):2969-2976.
27. Bermudez VP, Farina A, Hurwitz J, et al. Studies on human DNA polymerase epsilon and GINS complex and its role in DNA replication. J Biol Chem. 2011;286(23):28963-28977.
28. MacNeill SA. Structure and function of the GINS complex, a key component of the eukaryotic replisome. Biochem J. 2010;425(3):489-500.
29. Gong ZY, Kidoya H, Takakura N, et al. DNA damage enhanced by the attenuation of SLD5 delays cell cycle restoration in normal cells but not in cancer cells. PLoS ONE. 2014;9(10):e110483.
30. Chang L, Kariin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37-40.
31. Kidger AM, Sipthorp J, Cook SJ. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway. Pharmacol Ther. 2018;187:45-60.
32. Treinies I, Paterson HF, Marshall CJ, et al. Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal to stimulate DNA synthesis. Mol Cell Biol. 1999;19(1):321-329.
33. SmalleyI, Smalley KSM. ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers? Cancer Discov. 2018;8(2):140-142.
34. Arques O, Chicote I, Silberschmidt D, et al. Tankyrase Inhibition Blocks Wnt/beta-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res. 2016;22(3):644-656.
35. Lee JJ, Loh K, Yap YS. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 2015;12(4):342-354.
36. Wang Q, Zhou Y, Lee EY, et al. Deptor is a novel target of Wnt/beta-Catenin and contributes to colorectal cancer cell growth. Cancer Res. 2018;78(12):3163-3175.
37. Zhu Z, Rong Z, Huang C, et al. Circular RNA circNHS1L promotes gastric cancer progression through the miR-1306-3p/SIX1/vimentin axis. Mol Cancer. 2019;18(1):126.
38. Zhu Z, Yu Z, Huang C, et al. Krüppel-Like Factor 4 Inhibits Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis by Down-Regulating Caveolin-1 Expression. Cell Physiol Biochem. 2018;46(1):238-252.
39. PatelNV, Ghaele AM, Nandan MO, Yang VW. Expression of the tumor suppressor Kruppel-like factor 4 as a prognostic predictor for colon cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2631-2638.
40. Li D, Peng Z, Li Q, et al. KLF4-mediated negative regulation of IFITM3 expression plays a critical role in colon cancer pathogenesis. Clin Cancer Res. 2011;17(11):3558-3568.

How to cite this article: Rong Z, Luo Z, Zhang J, et al. GINS complex subunit 4, a prognostic biomarker and reversely mediated by Krüppel-like factor 4, promotes the growth of colorectal cancer. Cancer Sci. 2020;111:1203–1217. https://doi.org/10.1111/cas.14341